Emily Luisa Hill Sells 8,938 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Replimune Group Stock Up 1.7 %

Shares of REPL traded up $0.17 on Monday, reaching $10.28. The stock had a trading volume of 687,726 shares, compared to its average volume of 1,190,913. The firm has a market capitalization of $702.33 million, a price-to-earnings ratio of -3.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.72 and a current ratio of 13.46. The company has a 50-day simple moving average of $9.35 and a 200-day simple moving average of $7.99. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $21.32.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Sell-side analysts predict that Replimune Group, Inc. will post -3.15 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its holdings in shares of Replimune Group by 236.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock worth $35,000 after purchasing an additional 2,958 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the period. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the second quarter valued at about $57,000. Quest Partners LLC purchased a new position in shares of Replimune Group in the fourth quarter valued at about $76,000. Finally, Diversified Trust Co purchased a new position in shares of Replimune Group in the first quarter valued at about $94,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REPL. Wedbush reiterated an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. HC Wainwright lifted their price objective on Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. cut their price objective on Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Finally, Barclays lifted their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.